This book contains chapters written by experts in the field of the ubiquitin proteasome system and cancer. The authors have summarized current information on ubiquitin ligases and proteasomes as potential targets for cancer therapy. Topics covered in the book include an overview of ubiquitin ligases, deubiquitinating enzymes, and the proteasome. Specific diseases resulting from deregulated ubiquitin ligases, such as Von-Hippel-Lindau disease and Fanconi anemia are also discussed. Finally, novel approaches and drugs to target proteins involved in sumoylation, ubiquitination, and degradation are described.
|Publisher:||Springer New York|
|Edition description:||Softcover reprint of hardcover 1st ed. 2009|
|Product dimensions:||6.10(w) x 9.25(h) x 0.01(d)|
Table of ContentsUbiquitin Ligases and Cancer.- The 26S Proteasome as a Therapeutic Target in Cancer: Beyond Protease Inhibitors?.- Targeting HAUSP: Killing Two Birds with One Stone.- Modulation of Protein Stability: Targeting the VHL Pathway.- Interrelationship of the Fanconi Anemia/BRCA Pathway.- Targeting the Sumoylation Pathway.- Proteasome Inhibitors.- Targeting Deubiquitinating Enzymes.- Proteolysis Targeting Chimeric Molecules.